| Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer JH Strickler, H Satake, TJ George, R Yaeger, A Hollebecque, ... New England journal of medicine 388 (1), 33-43, 2023 | 232 | 2023 |
| Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors J García-Foncillas, Y Sunakawa, D Aderka, Z Wainberg, P Ronga, ... Frontiers in oncology 9, 849, 2019 | 168 | 2019 |
| Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer K Fujita, Y Ando, W Yamamoto, T Miya, H Endo, Y Sunakawa, K Araki, ... Cancer chemotherapy and pharmacology 65, 251-258, 2010 | 121 | 2010 |
| Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial K Nakachi, M Ikeda, M Konishi, S Nomura, H Katayama, T Kataoka, ... The Lancet 401 (10372), 195-203, 2023 | 98 | 2023 |
| Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network Y Sunakawa, HJ Lenz Current treatment options in oncology 16, 1-18, 2015 | 82 | 2015 |
| Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans K Fujita, T Sugiura, H Okumura, S Umeda, N Nakamichi, Y Watanabe, ... Pharmaceutical research 31, 204-215, 2014 | 66 | 2014 |
| Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics Y Sunakawa, J Furuse, T Okusaka, M Ikeda, F Nagashima, H Ueno, ... Investigational new drugs 32, 104-112, 2014 | 64 | 2014 |
| CYP2A6 and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in … K Fujita, W Yamamoto, S Endo, H Endo, F Nagashima, W Ichikawa, ... Cancer science 99 (5), 1049-1054, 2008 | 63 | 2008 |
| Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer H Bando, Y Nakamura, H Taniguchi, M Shiozawa, H Yasui, T Esaki, ... JCO Precision Oncology 6, e2100535, 2022 | 62 | 2022 |
| First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety JH Strickler, H Satake, A Hollebecque, Y Sunakawa, P Tomasini, ... Journal of Clinical Oncology 40 (36_suppl), 360490-360490, 2022 | 55 | 2022 |
| Targeting EGFR and RAS/RAF signaling in the treatment of metastatic colorectal cancer: from current treatment strategies to future perspectives T Mizukami, N Izawa, TE Nakajima, Y Sunakawa Drugs 79, 633-645, 2019 | 53 | 2019 |
| Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated … K Fujita, F Nagashima, W Yamamoto, H Endo, Y Sunakawa, K Yamashita, ... Biological and Pharmaceutical Bulletin 31 (11), 2137-2142, 2008 | 52 | 2008 |
| UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer Y Sunakawa, W Ichikawa, K Fujita, F Nagashima, H Ishida, K Yamashita, ... Cancer chemotherapy and pharmacology 68, 279-284, 2011 | 50 | 2011 |
| Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results … Y Sunakawa, S Stintzing, S Cao, V Heinemann, C Cremolini, A Falcone, ... Annals of Oncology 26 (12), 2450-2456, 2015 | 49 | 2015 |
| Genetic testing for UGT1A1* 28 and* 6 in Japanese patients who receive irinotecan chemotherapy Y Akiyama, K Fujita, F Nagashima, W Yamamoto, H Endo, Y Sunakawa, ... Annals of oncology 19 (12), 2089-2090, 2008 | 49 | 2008 |
| Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure K Fujita, Y Masuo, H Okumura, Y Watanabe, H Suzuki, Y Sunakawa, ... Pharmaceutical research 33, 269-282, 2016 | 46 | 2016 |
| Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis … Y Sunakawa, W Ichikawa, A Tsuji, T Denda, Y Segawa, Y Negoro, ... Clinical colorectal cancer 16 (3), e171-e180, 2017 | 44 | 2017 |
| Cytokeratin-20 and survivin-expressing circulating tumor cells predict survival in metastatic colorectal cancer patients by a combined immunomagnetic qRT-PCR approach Y Ning, DL Hanna, W Zhang, A Mendez, D Yang, R El-Khoueiry, ... Molecular cancer therapeutics 14 (10), 2401-2408, 2015 | 44 | 2015 |
| Plastin polymorphisms predict gender-and stage-specific colon cancer recurrence after adjuvant chemotherapy Y Ning, A Gerger, W Zhang, DL Hanna, D Yang, T Winder, T Wakatsuki, ... Molecular cancer therapeutics 13 (2), 528-539, 2014 | 43 | 2014 |
| Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric … T Jogo, Y Nakamura, K Shitara, H Bando, H Yasui, T Esaki, T Terazawa, ... Clinical cancer research 27 (20), 5619-5627, 2021 | 40 | 2021 |
